The clinical significance for the detection of plasma asymmetric dimethylarginine in patients with cerebral small vessel disease / 中华行为医学与脑科学杂志

ABSTRACT

ObjectiveTo study the relationship between the plasma level of asymmetric dimethylarginine (ADMA) and the damage degree of white matter and the changes of cognitive function in patients with cerebral small vessel disease.Methods120 patients with white matter lesions,induced by cerebral small vessel disease,were randomly selected.All patients were divided into group with or without cognitive dysfunction according to the results of MoCA scale.The plasma level of ADMA was detected with high-perfomance liquid chromatography method.Scheltens semi-quantitative evaluation was used to detect the damage degree of white matter.Correlation analysis was used to evaluate the relationship between the plasma level of ADMA and white matter lesions and cognitive dysfunction.ResultsThere were 42 patients with cognitive dysfunction and 78 patients without cognitive dysfunction.The plasma level of ADMA in patients with cognitive dysfunction ( ( 1.57 ±0.56) μg/ml) was significantly higher than patients without cognitive dysfunction ( (0.89 ±0.23 ) μg/ml) (P ＜ 0.01 ).Scheltens semi-quantitative evaluationfor patients with cognitive dysfunction and patients without cognitive dysfunction was 8.01 ± 2.50and 2.49 ± 0.59,respectively.There was significant difference between this two groups (P ＜ 0.01 ).The plasma level of ADMA positively correlated with the damage degree of white matter lesions and the changes of cognitive function.The correlation coefficients were 0.913 and 0.837,respectively ( All P ＜ 0.01 ).ConclusionADMA may be involved in the process of white matter damage caused by cerebral small vessel disease.The detection for plasma levels of ADMA may contribute to the prevention and early diagnosis of patients with cognitive dysfunction caused by cerebral small vessel disease.